Floatz logo

MB-07811

Hyperlipidemia

Viking Therapeutics, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Hyperlipidemia cohort.

Asset / SponsorPhaseRating
Lipitor
Poznan University of Medical Sciences
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
PRAVASTATIN
University of North Carolina, Chapel Hill
Phase 4BBB
Ezetimibe
NewAmsterdam Pharma
Phase 4BBB
Fenofibrate
Ospedale di Circolo - Fondazione Macchi
Phase 4BB

View all 36 →

Same molecule, other indications

MB-07811 is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
57 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →